Abstract: The invention relates to a peptide or peptide derivative having the general formula: Sub1-X1-D2K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12- P13-R14-X3-I16-P17/Y17-N18-N19-X4-Sub2, wherein X1 is a non-polar, hydrophobic group or a positively charged group, D2 is asparagine or glutamine, K3, X2, and X4 are positively charged groups, X3 is a positively charged group, proline, or a proline derivative: L7 and I16 are non-polar, hydrophobic groups, Y6 and Y17 are tyrosine, R9 and R14 are arginine, N18 and N19 are asparagine or glutamine, P4, P5, P8, P10, P12, P13 and P17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D2, P4, P5, P8, P10, P12, P13, P17 and Y17 are replaced by an arbitrary group and/or P13 and R14 are exchanged. Sub1 is the free or modified N-terminus, and Sub2 is the free or modified C-terminus.

Abstract: This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to composite and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as Staphylococcus aureus. According to the invention, the object is attained in a first aspect by a peptide according to claim 1.

Abstract: The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.

Abstract: Methods are described for stratifying patient risk for patients with prostate cancer and for providing a treatment recommendation to a patient based on a phosphodiesterase 4D variant 7 (PDE4D7) risk score. A diagnostic kit and a computer program product for the analysis and determination of the PDE4D7 risk score are also described.

Abstract: The invention relates to a method and means for the non-invasive diagnosis of type II diabetes mellitus. The glycation state is determined in at least one glycation position of selected plasma proteins.

Abstract: This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to compositions and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as Staphylococcus aureus. According to the invention, the object is attained in a first aspect by a peptide according to claim 1.

Abstract: The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.

Abstract: A polarized relay comprising an electromagnet, a two-pole or three-pole permanent magnet, an armature, and switches, which are mounted in and on a shelf-like support component. The support component accommodates magnetic flux pieces and the permanent magnet in an upper cavity, and the permanent magnet is magnetized while the electromagnet is still outside the support component. Subsequently, the electromagnet is inserted into lower cavity of the support component and the rest of the components of the relay are mounted.

Abstract: A coil assembly is provided, comprising a coil former, a coil, and a connection block which is pivotally joined to the coil former. The coil is wound while the connection block is pivoted away, the winding wire ends are soldered to the terminal pins, and the connection block is pivoted close to the coil.

Abstract: An electromechanical relay is provided, comprising a magnetic system and a pivotable armature. A diagnostic switch is arranged on one side of the relay, and the set of contacts of the diagnostic switch is driven by the adjacent leg of the armature. A load switch is arranged on the bottom side of the relay and is driven by the second leg of the armature via an insulating coupling member.

Abstract: This invention relates to modified antibiotic peptides, particularly for use in medicine. The invention further relates to compositions and methods for destroying microorganisms, such as bacteria, viruses or fungi, and to methods for treating microbial infections. The object of the invention is to develop novel antibiotic peptides, particularly having enhanced antibiotic activity and an expanded spectrum of activity against other strains of bacteria, particularly gram-positive bacteria such as Staphylococcus aureus. According to the invention, the object is attained in a first aspect by a peptide according to claim 1.

Abstract: This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub1-X1 N X2 X3 P V Y I P X4 X5 R P P H P-Sub2 wherein X1 is a neutral or positively charged moiety, X2 is a polar or positively charged moiety, X3 is a positively charged moiety, X4 is a polar or positively charged moiety, X5 is a proline or a proline derivate, Sub1 being the free or modified N-terminus, and Sub2 being the free or modified C-terminus.

Abstract: The invention relates to a peptide or peptide derivative having the general formula: Sub1-X1-D2K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12- P13-R14-X3-I16-P17/Y17-N18-N19-X4-Sub2, wherein X1 is a non-polar, hydrophobic group pr a positively charged group, D2 is asparagine or glutamine, K3, X2, and X4 are positively charged groups, X3 is a positively charged group, proline, or a proline derivative; L7 and I16 are non-polar, hydrophobic groups, Y6 and Y17 are tyrosine, R9 and R14 are arginine, N18 and N19 are asparagine or glutamine, P4, P5, P8, P10, P12, P13, and P17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D2, P4, P5, P8, P10, P12, P13, P17, and Y17 are replaced by an arbitrary group and/or P13 and R14 are exchanged, Sub1 is the free or modified N-terminus, and Sub2 is the free or modified C-terminus.

Abstract: The present invention relates to a method for preparation of a 2-chloro-1,10-phenanthrolinamine, comprising the steps: i) conversion of a 2-chloro-1,10-phenanthroline to a 2-chloro-nitro-1,10-phenanthroline characterized by a formula 2, j) hydrogenation of said 2-chloro-nitro-1,10-phenanthroline characterized by formula 5 to a 2-chloro-1,10-phenanthrolinaminecharacterized by formula 3. The present invention relates further to a method for preparation of a 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[carboxymethyl-[2-[4-[2-(isothiocyanato-1,10-phenanthrolin-2-yl)ethynyl]anilino]-2-oxo-ethyl]amino]ethyl]amino]acetic acidcharacterized by formula 7 and a method for quantifying a biomolecule in a sample.

Abstract: This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub1-X1 N X2 X3 P V Y I P X4 X5 R P P H P-Sub2 (SEQ ID NO:169) wherein X1 is a neutral or positively charged moiety, X2 is a polar or positively charged moiety, X3 is a positively charged moiety, X4 is a polar or positively charged moiety, X5 is a proline or a proline derivate, Sub1 being the free or modified N-terminus, and Sub2 being the free or modified C-terminus.

Abstract: A coil assembly is provided, comprising a coil former, a coil, and a connection block which is pivotally joined to the coil former. The coil is wound while the connection block is pivoted away, the winding wire ends are soldered to the terminal pins, and the connection block is pivoted close to the coil.

Abstract: A polarized relay comprising an electromagnet, a two-pole or three-pole permanent magnet, an armature, and switches, which are mounted in and on a shelf-like support component. The support component accommodates magnetic flux pieces and the permanent magnet in an upper cavity, and the permanent magnet is magnetized while the electromagnet is still outside the support component. Subsequently, the electromagnet is inserted into lower cavity of the support component and the rest of the components of the relay are mounted.

Abstract: An electromechanical relay is provided, comprising a magnetic system and a pivotable armature. A diagnostic switch is arranged on one side of the relay, and the set of contacts of the diagnostic switch is driven by the adjacent leg of the armature. A load switch is arranged on the bottom side of the relay and is driven by the second leg of the armature via an insulating coupling member.

Abstract: The present invention relates to contactors for unidirectional DC operation with permanent magnetic arc extinguishing. In addition to the blow magnets, the contactors are equipped with compensatory permanent magnets for compensating the magnetic field in the vicinity of the contact bridge in order to prevent contact levitation, i.e., an uncontrolled opening of the contacts that is due to a magnetic force generated by a strong current flowing through the contact bridge. To this end, the compensatory permanent magnets are arranged in the vicinity of the contact bridge and polarized in the opposite direction of the blow magnets. The magnetic field of the compensatory magnets and the current flowing through the contact bridge are generating a magnetic force that acts on the contact bridge and tends to keep the electrical contacts closed.

Abstract: The present invention relates to a antimicrobial peptide or peptide derivative comprising the following sequence: Sub1-X1-D2-K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-T16-P17-N18-N19-X4-Sub2. The invention further relates to multimers comprising said peptides or peptide derivatives. Moreover, the invention provides a peptide or peptide derivative for use in the treatment of a disease. The peptide or peptide derivative may also be used in the screening for novel antimicrobial compounds.